Sometimes pain is a necessary warning signal; for example, if we touch something very hot and it burns, we know to move our hand away. But chronic pain can destroy a person’s quality of life, and it can be extremely challenging to get relief. Some researchers have been searching for ways to deactivate pain receptors, so the body no longer feels the neural signals of chronic pain. Using mouse models of acute inflammatory pain, scientists have shown that it is possible to deactivate pain receptors with genetic engineering tools. The work has been reported in Cell.
“What we have developed is potentially a gene therapy approach for chronic pain,” said senior study author Bryan L. Roth, MD, PhD, a distinguished professor at the University of North Carolina (UNC) School of Medicine, among other appointments. “The idea is that we could deliver this chemogenetic tool through a virus to the neurons that sense the pain. Then, you could just take an inert pill and turn those neurons off, and the pain will literally disappear.”
What causes autism? It isn’t vaccines, studies show. Here are some possibilities that researchers are exploring.
There is no one factor that causes autism — or explains its growing prevalence. Researchers are seeking explanations for the surge. Here are some possibilities.
Researchers with the Advanced Science Research Center at the CUNY Graduate Center (CUNY ASRC) have unveiled a critical mechanism that links cellular stress in the brain to the progression of Alzheimer’s disease (AD).
The study, published in the journal Neuron, highlights microglia, the brain’s primary immune cells, as central players in both the protective and harmful responses associated with the disease.
Microglia, often dubbed the brain’s first responders, are now recognized as a significant causal cell type in Alzheimer’s pathology. However, these cells play a double-edged role: some protect brain health, while others worsen neurodegeneration.
Whenever a sink overflows, the flooding is usually caused by a blockage that has built up in the drains. Similarly, as we age, our bodies are flooded by aging, or senescent cells, which have stopped dividing but, instead of dying, remain active and build up in body tissues. Recent studies have shown that getting rid of these cells might delay age-related diseases, reduce inflammation and extend lives. Despite the great potential, however, there is currently no drug that can target these cells directly and efficiently.
Now, Weizmann Institute of Science researchers suggest an alternative approach. In a new study published in Nature Cell Biology, they reveal that senescent cells build up in the body by clogging up the immune system, thereby preventing their own removal.
The scientists demonstrated in mice how to unclog this blockage using immunotherapy, the new generation of treatments that is revolutionizing cancer therapy. These findings could pave the way for innovative treatment of age-related diseases and other chronic disorders.
Here’s one definition of science: it’s essentially an iterative process of building models with ever-greater explanatory power.
A model is just an approximation or simplification of how we think the world works. In the past, these models could be very simple, as simple in fact as a mathematical formula. But over time, they have evolved and scientists have built increasingly sophisticated simulations of the world as new data has become available.
A computer model of the Earth’s climate can show us temperatures will rise as we continue to release greenhouse gases into the atmosphere. Models can also predict how infectious disease will spread in a population, for example.
Cytomegalovirus (CMV), which causes a cold-like illness, can be spread in the same way as other viruses from person to person through body fluids such as blood, saliva and urine.
But the infection is present in up to 45 per cent of Alzheimer’s cases, US scientists have claimed.
Some people exposed to the bug may develop a chronic intestinal infection, allowing it to enter the bloodstream and travel to the brain.
Alzheimer’s disease (AD) is a debilitating neurodegenerative disorder associated with a progressive decline in memory and mental abilities, which can significantly hinder people’s ability to complete daily tasks. Past studies found that patients diagnosed with AD, as well as some other neurodegenerative disorders, exhibit an abnormal accumulation of tau protein in their neurons.
Tau protein is a microtubule-associated protein (MAP) known to stabilize the internal structure of neurons, binding to microtubules. These are microscopic tubular structures that support the transport of nutrients, proteins and other vital molecules within individual neurons or other cells.
Recent findings suggest that tau proteins interact with extracellular vesicles (EVs), small membrane-bound particles secreted by cells that carry molecules and deliver them to other cells. While the research hints at a connection between these vesicles and tau proteins in AD, the link between the two is not yet fully understood.
Monitoring electrical potentials with high recording site density and micrometer spatial resolution in liquid is critical in biosensing. Organic electronic materials have driven remarkable advances in the field because of their unique material properties, yet limitations in spatial resolution and recording density remain. Here, we introduce organic electro-scattering antennas (OCEANs) for wireless, light-based probing of electrical signals with micrometer spatial resolution, potentially from thousands of sites. The technology relies on the unique dependence of poly(3,4-ethylenedioxythiophene):polystyrene sulfonate light scattering properties to its doping level. Electro-optic characteristics of individual antennas varying in diameters and operating voltages were systematically characterized in saline solution. Signal-to-noise ratios up to 48 were achieved in response to 100-mV stimuli, with 2.5-mV detection limits. OCEANs demonstrated millisecond time constants and exceptional long-term stability, enabling continuous recordings over 10 hours. By offering spatial resolution of 5 μm and a recording density of 4 × 106 cm−2, OCEANs unlock new readout capabilities, potentially accelerating fundamental and clinical research.
Bioconvergence — Bridging Science And Nature To Shape Tomorrow — Dr. Nina Siragusa Ph.D. — Merck KGaA, Darmstadt, Germany
#NinaSiragusa #MerckGroup #Darmstadt.
Dr. Nina Siragusa, Ph.D., MBA, is the Strategy, Business, and Data & Digital Lead within the global R&D organization of Merck Healthcare KGaA, Darmstadt, Germany. In this role, she leads strategic projects, manages business operations, and drives digital transformation.
Previously, she served as Chief of Staff to Dr. Laura Matz, Chief Science and Technology Officer at Merck KGaA, Darmstadt, Germany. As part of the Science and Technology Office Leadership Team, she was responsible for fostering cross-sectoral collaboration, innovation, and digitalization across Merck’s three business sectors. She also spearheaded the company’s efforts in Bioconvergence, a multidisciplinary approach that synergizes biology, engineering, data, and digitalization. This initiative promises groundbreaking advancements in healthcare and the life sciences, heralding a new era of scientific collaboration for a healthier, more sustainable future.
Prior to that, Dr. Siragusa contributed to corporate innovation in several leadership roles:
